医学と薬学 78/2 2021年2月号

出版社: 自然科学社
発行日: 2021-01-27
分野: 薬学  >  雑誌
ISSN: 03893898
雑誌名:
特集: 敗血症―再考,そして未来へ(I)
電子書籍版: 2021-01-27 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:4~8営業日

2,200 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,760 円(税込)

目次

  • 特集 敗血症―再考,そして未来へ(I)

    序文
    敗血症定義の変遷
    敗血症の疫学
    敗血症の病態生理
    敗血症と液性因子
    敗血症とエンドトキシン

    薬理・薬剤
     マウスのガラス玉覆い隠し行動に対するメマンチン塩酸塩OD錠「ニプロ」の抑制効果

    研究
     四塩化炭素および肝臓X受容体アゴニストの投与による
      非アルコール性脂肪性肝炎モデルに対するBezafibrateの作用

    Diagnosis
     アクセス25(OH)ビタミンD Total+を用いた基礎的検討
     CKD患者においてBNP・NT-proBNP濃度をどのように評価すべきか
    「LZ テスト‘栄研’hSAA」の臨床化学自動分析装置への適応検討

    Health care
     口臭予防サプリメントRe:CLEAR(リクリア)を使用した口臭低減効果測定
      ―単群非ランダム化オープン臨床試験―

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 敗血症 - 再考, そして未来へ ( I ) 】

P.115 掲載の参考文献
1) Geroulanos S, Douka ET : Historical perspective of the word "sepsis". Intensive Care Med 32 (12) : 2077, 2006.
2) Budelmann G : Hugo Schottmuller, 1867-1936. The problem of sepsis. Internist (Berl) 10 (3) : 92-101, 1969.
3) Bone RC, Balk RA, Cerra FB, et al : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 (6) : 1644-1655, 1992
4) Abraham E, Matthay MA, Dinarello CA, et al : Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome : time for a reevaluation. Crit Care Med 28 (1) : 232-235, 2000.
5) Levy MM, Fink MP, Marshall JC, et al : 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (4) : 1250-1256, 2003.
6) Jean-Louis Vincent, Steven M Opal, John C Marshall, et al : Sepsis definitions : time for change. Lancet 381 (9868) : 774-775, 2013.
7) Huifang Zhao, Stephen O Heard, Marie T Mullen, et al : An evaluation of the diagnostic accuracy of the 1991 American College of Chest Physicians/Society of Critical Care Medicine and the 2001 Society of Critical Care Medicine/European Society of Intensive Care Medicine/American College of Chest Physicians/American Thoracic Society/Surgical Infection Society sepsis definition. Crit Care Med 40 (6) : 1700-1706, 2012.
8) Singer M, Deutschman CS, Seymour CW, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8) : 801-810, 2016.
9) JL Vincent, R Moreno, J Takala, et al : The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 (7) : 707-710, 1996.
10) Ferreira FL, Bota DP, Bross A, et al : Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286 (14) : 1754-1758, 2001.
11) Seymour CW, Liu VX, Iwashyna TJ, et al : Assessment of Clinical Criteria for Sepsis : For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8) : 762-774, 2016.
12) Raith EP, Udy AA, Bailey M, et al : Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. JAMA 317 (3) : 290 -300, 2017
13) E Abraham : New Definitions for Sepsis and Septic Shock : Continuing Evolution but With Much Still to Be Done. JAMA 315 (8) : 757-759, 2016.
14) Simpson SQ : New Sepsis Criteria : A Change We Should Not Make. Chest 149 (5) : 1117-1118, 2016.
15) Reith FC, Brennan PM, Maas AI, et al : Lack of Standardization in the Use of the Glasgow Coma Scale : Results of International Surveys. J Neurotrauma 33 (1) : 89 -94, 2016.
P.120 掲載の参考文献
1) Fleischmann C, Scherag A, Adhikari NK, et al : Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193 (3) : 259-272, 2016.
2) Ogura H, Gando S, Saitoh D, et al : Epidemiology of severe sepsis in Japanese intensive care units : a prospective multicenter study. J Infect Chemother 20 (3) : 157-162, 2014.
3) Rudd KE, Johnson SC, Agesa KM, et al : Global, regional, and national sepsis incidence and mortality, 1990-2017 : analysis for the Global Burden of Disease Study. Lancet 395 (10219) : 200-211, 2020.
4) Angus DC, Linde-Zwirble WT, Lidicker J, et al : Epidemiology of severe sepsis in the United States : analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (7) : 1303-1310, 2001.
5) 厚生労働省院内感染対策サーベイランス事業 : https://janis.mhlw.go.jp/report/icu.html
6) Vincent JL, Sakr Y, Sprung CL, et al : Sepsis in European intensive care units : results of the SOAP study. Crit Care Med 34 (2) : 344-353, 2006.
7) 松田直之, 織田成人, 相引眞幸, 他 : 日本集中治療医学会 第1回 Sepsis Registry調査-2007年の重症敗血症および敗血症性ショックの診療結果報告-. 日集中医誌 20 (2) : 329-334, 2013.
8) Vincent JL, Bihari DJ, Suter PM, et al : The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274 (8) : 639-644, 1995.
9) 遠藤重厚, 鈴木泰, 小鹿雅博, 他 : Surviving Sepsis Campaign Guideline (SSCG) 2008により敗血症の救命率は向上したか? Shock 26 (2) : 58-66, 2012.
10) Knaus WA, Draper EA, Wagner DP, et al : APACHE II : a severity of disease classification system. Crit Care Med 13 (10) : 818-829, 1985.
11) Vincent JL, Moreno R, Takala J, et al : The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. on behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 (7) : 707-710, 1996.
12) Singer M, Deutschman CS, Seymour CW, et al : The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315 (8) : 801-810, 2016.
P.127 掲載の参考文献
1) Singer M, Deutschman CS, Seymour CW, et al : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016.
2) Bianchi ME : DAMPs, PAMPs and alarmins : all we need to know about danger. J Leukoc Biol 81 : 1-5, 2007.
3) Matsumoto H, Ogura H, Shimizu K, et al : The clinical importance of a cytokine network in the acute phase of sepsis. Scientific reports 8 : 13995, 2018.
4) Backer DD, Creteur J, Preiser JC, et al : Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166 : 98-104, 2002.
5) Edul VS, Enrico C, Laviolle B, et al : Quantitative assessment of the microcirculation in healthy volunteers and in patients with septic shock. Crit Care Med 40 : 1443-1448, 2012.
6) Siner M : The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 5 : 66-72, 2014.
7) Brealey D, Brand M, Hargreaves I, et al : Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 9328 : 219-223, 2002.
8) Carre JE, Orban J-C, Re L, et al : Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 182 : 745-751, 2010.
9) Boelen A, Kwakkel J, Fliers E : Beyond low plasma T3 : local thyroid hormone metabolism during inflam-mation and infection. Endocr Rev 32 : 670-693, 2011.
10) Ogura H, Gando S, Iba T, et al : SIRS-associated coagulopathy in critically ill patients with thrombocytopenia. Shock 28 : 411-418, 2007.
11) Levi M, Keller T, van Gorp E, et al : Infection and inflammation and the coagulation system. Cardiovas Res 60 : 26-39, 2003.
12) Hoffman M, Monroe DM 3rd : A cell-based model of hemostasis. Thromb Haemost 85 : 958-965, 2001.
13) Brinkmann V, Reichard U, Goosmann C, et al : Neutrophil extracellular traps kill bacteria. Science 303 : 1532-1535, 2004.
14) Ogura H, Tanaka H, Koh T, et al : Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. J Trauma 56 : 823-830, 2004.
15) Ogura H, Kawasaki T, Tanaka H, et al : Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 50 : 801-809, 2001.
16) Ekaney ML, Otto GP, Sossdorf M, et al : Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation. Crit Care 18 : 543, 2014.
17) Xu J, Zhang X, Pelayo R, Monestier M, et al : Extracellular histones are major mediators of death in sepsis. Nat Med 15 : 1318-1321, 2009.
18) Iba T, Levy JH : Derangement of the endothelial glycocalyx in sepsis. Journal of Thrombosis and Haemostasis 17 : 283-294, 2019.
19) Ikeda M, Matsumoto H, Ogura H, et al : Circulating syndecan-1 predicts the development of disseminated intravascular coagulation in patients with sepsis. J Crit Care 43 : 48-53, 2018.
20) Hotchkiss RS, Strasser A, McDunn JE, et al : Cell death. N Engl J Med 361 : 1570-1583, 2009.
21) Degterev A, Huang Z, Boyce M, et al : Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1 : 112-119, 2005.
22) Duprez L, Takahashi N, Van Hauwermeiren F, et al : RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 35 : 908-918, 2011.
23) Watanabe E, Muenzer JT, Hawkins WG, et al : Sepsis induces extensive autophagic vacuolization in hepatocytes : a clinical and laboratory-based study. Lab Invest 89 : 549-561, 2009.
24) Takahashi W, Watanabe E, Fujimura L, et al : Kinetics and protective role of autophagy in a mouse cecal ligation and puncture-induced sepsis. Crit Care 17 : R160, 2013.
P.133 掲載の参考文献
1) Hotchkiss RS, Monneret G, Payen D : Sepsis-induced immunosuppression : from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13 : 862-827, 2013.
2) Suzuki T, Suzuki Y, Okuda J, et al : Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. J Intensive Care 5 : 22, 2017.
3) Harris HE, Raucci A : Alarmin (g) news about danger : workshop on innate danger signals and HMGB1. EMBO Rep 7 : 774-778, 2006.
4) Cinel I, Opal SM : Molecular biology of inflammation and sepsis : a primer. Crit Care Med 37 : 291-304, 2009.
5) 渡邊栄三 : 敗血症の病態生理 Up to date炎症と免疫・免疫麻痺. ICUとCCU 44 (2) : 57-64, 2020.
6) Doi K, Leelahavanichkul A, Hu X, et al : Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int 74 : 1017-1025, 2008.
7) Arens C, Bajwa SA, Koch C, et al : Sepsis-induced long-term immune paralysis-results of a descriptive, explorative study. Crit Care 20 : 93, 2016.
8) Ronco C, Tetta C, Mariano F, et al : Interpreting the mechanisms of continuous renal replacement therapy in sepsis : the peak concentration hypothesis. Artif Organs 27 : 792-801, 2003.
9) 鈴木泰, 柴田繁啓, 高橋学, 他 : PMX-DHP治療における酸化ストレス度への影響. エンドトキシン血症救命治療研究会誌 11 (1) : 56 -58, 2007.
10) 佐藤諒, 高橋学, 松本尚也, 他 : PMX-DHP施行時にtype II phospholipase A2 と肺酸素化能を継続して検討した1症例. エンドトキシン血症救命治療研究会 18 (1) : 127 -133, 2014.
11) Creasey AA, Reinhart K : Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 29 : 126-129, 2001.
13) Landry DW, Oliver JA : The pathogenesis of vasodilatory shock. N Engl J Med 345 : 588-595, 2001.
14) Ball BA, Cook JA, Wise WV, et al : Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. Intensive Care Med 12 : 116-126, 1986.
15) Landy DW, Levin HR, Gallant EM, et al : Vasopressin deficiency contributes to the vasodialation of septic shock. Circulation 95 : 1122-1125, 1997.
17) Galley HF : Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anesth 107 : 57-64, 2011.
18) Brinkmann V, Reichard U, Goosmann C, et al : Neutrophil extracellular traps kill bacteria. Science 5 : 1532-1535, 2004.
19) Volker Brinkmann, Arturo Zychlinsky : Beneficial suicide : why neutrophils die to make NETs. Nat Rev Microbiol 5 : 577-582, 2007.
20) Fuchs TA, Brill A, Duerschmied D : Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 7 : 15880-15885, 2010.
21) Nakahara M, Ito T, Kawahara K, et al : Recom-binant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One 30 : e75961, 2013.
22) Miyashita T, Ahmed AK, Nakanuma S, et al : A Three-phase Approach for the Early Identification of Acute Lung Injury Induced by Severe Sepsis. In Vivo 30 : 341-349, 2016.
P.140 掲載の参考文献
1) Fildes P : Richard Friedrich Johannes Pfeiffer, 1858-1945. Biogr Mem Fellows R Soc 2 : 237-247, 1956.
2) Bone RC : The pathogenesis of sepsis. Ann Intern Med 115 (6) : 457-469, 1991.
3) Ames GF, Spudich EN, Nikaido H : Protein composision of the outer membrane of Salmonella typhimurium : effect of lipopolysaccharide mutations. J Bacteriol 117 (2) : 406 -416, 1974.
4) 棚元憲一 : エンドトキシンと医薬品の品質管理. Bull Natl Inst Health Sci 126 : 19-33, 2008.
5) America College of Chest Phyisicians/Society of Critical Care Medicine Consensus Conference : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 (6) : 864-874, 1992.
6) Miyake K : Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 12 (4) : 195 -204, 2006.
7) Opal SM, Laterre PF, Framcpos B, et al : ACCESS Study Group : Effect of eritoran, an antagonist of MD2-TLR4 on mortality in patients with severe sepsis : the ACCESS randomized trial. JAMA 309 (11) : 1154-1162, 2013.
8) Shiga H, Hirasawa H, Nishida O, et al : Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock : a preliminary report. Blood Purif 38 (3-4) : 211 -218, 2014.
9) Kayagaki N, Wong MT, Stowe IB, et al : Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341 (6151) : 1246-1249, 2013.
10) Hagar JA, Powell DA, Aachoui Y, et al : Cytoplasmic LPS activates caspase-11 : implications in TLR4-independent endotoxin shock. Science 341 (6151) : 1250-1253, 2013.
11) Stowe I, Lee B, Kayagaki N : Caspase-11 : arming the guards against bacterial infection. Immunol Rev 265 (1) : 75 -84, 2015.
12) Wallach D, Kang TB, Dillon CP, et al : Programmed necrosis in inflammation : toward identification of the effector molecules. Science 352 (6281) : aaf 2154, 2016.
13) 森山和広, 山下千鶴, 西田修 : 基礎的な見地からみた血中エンドトキシン除去の意義. 日急性血浄化会誌 11 (1) : 9 -16, 2020.
14) Deng M, Tang Y, Wang X, et al : The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity 49 (4) : 740-753, 2018.
15) Zanoni I, Tan Y, Gioia M Di, et al : An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science 352 : 1232-1236, 2016.
16) Cheng KT, Xiong S, Ye Z, et al : Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced lung injury. J Clin Invest 127 (11) : 4124-4135, 2017.
17) Matthay MA, Zemans RL, Zimmerman GA, et al : Acute respiratory distress syndrome. Nat Rev Dis Primers 5 (1) : 18, 2019.
18) Miao N, Yin F, Xie H, et al : The cleavage of gasdermin D by caspase-11 promotes tubular epithelial cell pyrotptosis and urinary IL-18 excretion in acute kidney injury. Kidney Int 96 (5) : 1105 -1120, 2019.
19) Ye B, Chen X, Dai S, et al : Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes. Drug Des Devel Ther 13 : 975-990, 2019.
20) Nakano D, Doi K, Kitamura H, et al : Reduction of tubular flow rate as a mechanism of oliguria in the early phase of endotoxemia revealed by intravital imaging. J Am Soc Nephrol 26 (12) : 3035-3044, 2015.
21) Inada K, Endo S, Takahashi K, et al : Establishment of a new perchloric acid treatment method to allow determination of the total endotoxin content in human plasma by the limulus test and clinical application. Microbiol Immunol 35 (4) : 303-314, 1991.
22) 八重樫泰法, 稲田捷也, 佐藤信博, 他 : 血漿高感度エンドトキシン測定法について. エンドトキシン血症救命治療研会誌 7 (1) : 25-28, 2003.
23) Kan S, Takahashi G, Onodera C, et al : Evaluation of an endotoxin-specific limulus amebocyte lysate assay using leukocyte-rich plasma for the diagnosis of gram-negative bacterial infection. J Infect Chemother 19 (2) : 299-304, 2013.
24) Marshall JC, Walker PM, Foster DM, et al : Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 6 (4) : 342-348, 2002.
25) Munford RS : Endotoxemia-menace, marker, or mistake? J Leukoc Biol 100 (4) : 687-698, 2016.
26) Matsumoto N, Takahashi G, Kojika M, et al : Interleukin-8 indeces an elevation in the endotoxin activity assay (EAA) level : does the EAA truly measure the endotoxin level? J Infect Chemother 19 (5) : 825 -832, 2013.
27) Romaschin AD, Harris DM, Ribeiro MB, et al : A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods 212 (2) : 169-185, 1998.

【薬理・薬剤】

P.148 掲載の参考文献
1) 山口拓, 吉岡充弘 : 不安関連行動の評価法. 日薬理誌 130 (2) : 105-111, 2007.
2) Njung'e K, Handley SL : Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice ; a putative test for anxiolytic agents. Br J Pharmacol 104 (1) : 105-112, 1991.
3) Egashira N, Okuno R, Harada S, et al : Effects of glutamate-related drugs on marble-burying behavior in mice : implications for obsessive-compulsive disorder. Eur J Pharmacol 586 (1-3) : 164-170, 2008.
4) Frankiewicz T, Parsons CG : Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 38 (9) : 1253-1259, 1999.
5) 砂山友希, 服部綾香, 山崎淳治, 他 : メマンチン塩酸塩OD錠の製造およびその品質評価. 医学と薬学 77 (6) : 925-936, 2020.
6) Broekkamp CL, Rijk HW, Joly-Gelouin D, et al : Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126 (3) : 223-229, 1986.
7) Rorick-Kehn L M, Johnson B G, Knitowski K M, et al : In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193 (1) : 121-136, 2007.
8) Shimazaki T, Lijima M, Chaki S, et al : Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol 501 (1-3) : 121-125, 2004.
9) Lopez OL, Becker JT, Sweet RA, et al : Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 15 (3) : 346-353, 2003.
10) 認知症疾患診療ガイドライン 2017. 日本神経学会監, 「認知症疾患診療ガイドライン」作成委員会編, 医学書院, 東京, 2017.
11) 中村祐, 本間昭, 北村伸, 他 : 新規NMDA受容体拮抗剤であるメマンチン塩酸塩の中等度から高度アルツハイマー型認知症に対する第III相試験-有効性および安全性の検討-. 老年精神医学 22 (4) : 464-473, 2011.
12) 中村祐 : メマンチン. 日本生物学的精神医学会誌 22 (4) : 227-235, 2011.
13) メマリー錠・OD錠・ドライシロップ 医薬品インタビューフォーム (2020年8月改訂, 第17版).
14) Mattson MP, Chan SL : Neuronal and glial calcium signaling in Alzheimer's disease. Cwll Calcium 34 (4-5) : 385-397, 2003.
15) Takeda A, Tamano H, Kan F, et al : Enhancement of social isolation-induced aggressive behavior of young mice by zinc deficiency. Life Sci 82 (17-18) : 909-914, 2008.
16) Peters ME, Schwartz S, Han D, et al : Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death : the Cache County Dementia Progression Study. Am J Psychiatry 172 (5) : 460-465, 2015.

【研究】

P.156 掲載の参考文献
1) 金守良, 金啓二 : わが国におけるNAFLD/NASHの展望. YAKUGAKU ZASSHI 136 (4) : 565-572, 2016.
2) Watanabe S, Hashimoto E, Ikejima K, et al : Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 50 : 364-377, 2015.
3) 竹原徹郎 : NAFLD/NASHの病態研究 : 最近の動向. 日消誌 114 : 807-812, 2017.
4) Day CP, James OF : Steatohepatitis : A Tale of Two "Hits"? Gastroenterology 114 : 842-845, 1998.
5) 須藤正幸, 松本雅彦 : 創薬に向けた新たなNASH動物モデルの開発 肝代謝疾患である非アルコール性脂肪肝炎 (NASH) の創薬アプローチ. 日薬理誌 144 : 69-74, 2014.
6) 常山幸一 : 少ない介入で作製するメタボリックシンドローム関連肝疾患モデル動物のヒト病態解析への有用. 肝臓 59 (2) : 92-101, 2018.
7) Kishina M, Koda M, Kato J, et al : Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice. Hepatol Res 44 (8) : 888-896, 2014.
8) Sahai A, Malladi P, Pan X, et al : Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis : role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287 : G1035-G1043, 2004.
9) Watanabe S, Horie Y, Suzuki A : Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol Res 33 (2) : 161-166, 2005.
10) Shiota G : Loss of function of retinoic acid in liver leads to steatohepatitis and liver tumor : A NASH animal model. Hepatol Res 33 (2) : 155-160, 2005.
11) Nagasawa T, Inada Y, Nakano S, et al : Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 24 : 536 (1-2) : 182-191, 2006.
12) Shimozono R, Asaoka Y, Yoshizawa Y, et al : Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol 84 (1) : 62-70, 2013.
13) Matsumoto M, Hada N, Sakamaki Y, et al : An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol 94 (2) : 93-103, 2013.
14) Tsurusaki S, Tsuchiya Y, Koumura T, et al : Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis 10 (6) : 449, 2019.
15) 平澤康史, 杉浦孝宏, 川崎由紀子, 他 : Bezafibrate, TelmisartanおよびPioglitazoneの非アルコール性脂肪性肝炎モデルに対する作用. 医学と薬学 71 (2) : 293-301, 2014.
16) 川崎由紀子, 平澤康史, 杉浦孝宏, 他 : α-トコフェロールおよびアスコルビン酸のラットを用いた非アルコール性脂肪性肝炎モデルに対する作用. 薬理と臨床 24 (4) : 195-201, 2014.
17) Owada Y, Tamura T, Tanoi T, et al : Novel non-alcohlic steatohepatitis model with histopathological and insulin-resistant features. Pathology International 68 : 12-22, 2018.
18) 草間寛, 西山雅彦, 松原靖人, 他 : 抗高脂血症剤Bezafibrateの薬理学的研究 (2). -血清トリグリセライドおよびコレステロール低下作用機作の解析-. 日薬理誌 92 : 181-191, 1988.
19) 米田正人, 藤田浩司, 中島 淳, 他 : PPARγリガンドを用いた非アルコール性脂肪性肝炎 (NASH) の治療戦略. 日薬理誌 128 : 235-238, 2006.
20) Inoue I, Noji S, Shen MZ, et al : The peroxisome proliferator-activated receptor alpha (PPAR alpha) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level. Biochem Biophys Res Commun 237 (3) : 606-610, 1997.

【Diagnosis】

P.166 掲載の参考文献
1) 三浦雅一, 佐藤友紀 : 骨粗鬆症の診断と治療における25-ヒドロキシビタミンD測定の意義. The Journal of Japan Osteoporosis Society 2 : 375-381, 2016.
2) Tanaka S, Kuroda T, Yamazaki Y, et al : Serum 25-hydroxyvitamin D below 25ng/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women. J Bone Miner Metab 32 : 514-523, 2013.
3) Yoshimura N, Muraki S, Oka H, et al : Profiles of vitamin D insufficiency and deficiency in Japanese men and women : association with biological, environmental, and nutritional factors and coexisting disorders : the ROAD study. Osteoporosis Int 24 : 2775-2787, 2013.
4) J Tamaki, M Iki, Y Sato, et al : Total 25-hydroxyvitamin D levels predict fracture risk : results from the 15-year follow-up of the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporosis International 28 : 1903-1913, 2017.
5) 一般社団法人日本内分泌学会, 一般社団法人日本骨代謝学会, 厚生労働省難治性疾患克服研究事業ホルモン受容機構異常に関する調査研究班 : ビタミンD不足・欠乏の判定指針. 日本内分泌学会雑誌 93 (Suppl) : 2017.
6) 厚生労働省「日本人の食事摂取基準」策定検討会報告書 : 日本人の食事摂取基準 (2020年版), pp. 178-187, 2019.
7) 上田哲也, 若林弘樹, 三浦雅一 : ビタミンの測定法の進歩. 検査と技術 35 : 647-653, 2007.
8) 渭原博, 木内幸子 : 日本における総25水酸化ビタミンD測定の標準化と今後の課題. THE BONE 33 : 201-205, 2019.
9) 糸賀仁美, 畑伸顕, 前田育宏, 日高洋 : アクセス25 (OH) ビタミンD Total 試薬+を用いた基礎的検討とNST介入. 医学と薬学 76 : 1303-1310, 2019.
10) 川村隆志, 小野寺一哉, 千葉敏也 : ビオチンの影響を受けない測定試薬「アクセスインタクトPTH」の基礎的検討. 日本臨床検査自動化学会会誌 35 (5) : 888-892, 2010.
P.172 掲載の参考文献
1) Tsutsui H, et al : Characteristics and Outcomes of Patients With Heart Failure in General Practices and Hospitals Japanese Cardiac Registry of Heart Failure in General Practice (JCARE-GENERAL). Circ J 71 : 449-454, 2007.
2) 今井圓裕 : 高齢者の慢性腎臓病 (CKD) 日老医誌 51 : 385-400, 2014.
3) 慢性心不全治療ガイドライン (2018年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf
6) McCullough PA, et al : B-type natriuretic peptide and renal function in the diagnosis of heart failure : an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 4 : 571-579, 2003.
P.181 掲載の参考文献
1) Shainkin-Kestenbaum R, Zimlichman S, Winikoff Y, et al : Serum amyloid A (SAA) in viral infection : rubella, measles and subacute sclerosing panencephalitis (SSPE). Clin Exp Immunol 50 (3) : 503-506, 1982.
2) Sarov I, Shainkin-Kestenbaum R, Zimlichman S, et al : Serum amyloid A levels in patients with infections due to cytomegalovirus, varicella-zoster virus, and herpes simplex virus. J Infect Dis 146 (3) : 443, 1982.
3) Whicher JT, Chambers RE, Higginson J, et al : Acute phase response of serum amyloid A protein and C reactive protein to the common cold and influenza. J Clin Pathol 38 (3) : 312-316, 1985.
4) Casl MT, Sabljar-Matovinovic M, Kovacevic S, et al : Clinical relevance of serum amyloid A protein monitoring in urinary tract infections. Ann Clin Biochem 30 : 272-277, 1993.
5) Miwata H, Yamada T, Okada M, et al : Serum amyloid A protein in acute viral infections. Arch Dis Child 68 (2) : 210-214, 1993.
6) Nakayama T, Sonoda S, Urano T, et al : Monitoring both serum amyloid protein A and C-reactive protein as inflammatory makers in infectious diseases. Clin Chem 39 (2) : 293-297, 1993.
7) Raynes JG, Cooper EH : Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol 36 (7) : 798-803, 1983.
8) Shainkin-Kestenbaum R, Winikoff Y, Cristal N : Serum amyloid A concentrations during the course of acute ischaemic heart disease. J Clin Pathol 39 (6) : 635-637, 1986.
9) Chambers RE, MacFarlane DG, Whicher JT, et al : Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis 42 (6) : 665-667, 1983.
10) Maury CPJ : Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci 68 (2) : 233-238, 1985.
11) Wilkins J, Gallimore JR, Tennent GA, et al : Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 40 (7 Pt 1) : 1284-1290, 1994.
12) 秦越, 菊池達範, 木村明, 他 : 汎用自動分析装置を用いたLZテスト '栄研' hSAAの基本性能. 医療と検査機器・試薬 43 (4) : 404-409, 2020.
13) Tonks DB : A study of the accuracy and precision of clinical chemistry determinations in 170 Canadian laboratories. Clin Chem 9 : 217-233, 1963.
14) 細田智弘, 伊藤守, 永江真也, 他 : 大型クルーズ船内で発生した新型コロナウイルス感染者11例の臨床経過報告. 感染症学雑誌 94 (4) : 500-506, 2020.

【Health care】

P.186 掲載の参考文献
1) Hee-Eun Jin, Jae-Chul Choi, Yong Taik Lim, Moon-Hee Sung : Prebiotic Effects of Poly-Gamma-Glutamate on Bacterial Flora in Murine Gut. J Microbiol Biotechnol 27 (2) : 412-415, 2017.
2) 古泉巖, 鈴木嘉彦, 志村純子 : シャンピニオンエキスの消臭効果と生体内インドール, トリプタミン生成抑制効果. 日本公衛誌 44 (1) : 5-11, 1997.
3) 渋谷耕司 : 生理的口臭の成分と由来に関する研究. 口腔衛生会誌 51 : 778-792, 2001.
4) 齊藤幸枝, 大森みさき, 葛城啓彰 : 生理的口臭の要因に関する研究. 日歯周誌 44 (2) : 168-177, 2002.
5) 藤岡陽介, 両角俊哉, 久保田健彦, 吉江弘正 : 慢性歯周炎患者の歯周病原細菌および揮発性硫黄化合物に対する包括的口腔ケアの効果. 日歯保存誌 56 (6) : 551-559, 2013.
6) 宮崎秀夫 : エビデンスに基づく口臭試験. 明倫紀要 14 (1) : 3-8, 2011.

最近チェックした商品履歴

Loading...